5T4 as a target for immunotherapy in renal cell carcinoma

References

• McLaughlin JK, Lipworth L, Tarone RE. Epidemiologic aspects of renal cell carcinoma. Semin. Oncol.33, 527–533 (2006).
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol.17, 2530–2540 (1999).
   PubMed Web of Science ®Google Scholar
• Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med.353, 2477–2490 (2005).
   PubMed Web of Science ®Google Scholar
• Yagoda A, Bander NH. Failure of cytotoxic chemotherapy, 1983–1988, and the emerging role of monoclonal antibodies for renal cancer. Urol. Int.44, 338–345 (1989).
   PubMed Web of Science ®Google Scholar
• Harris DT. Hormonal therapy and chemotherapy of renal-cell carcinoma. Semin. Oncol.10, 422–430 (1983).
   PubMed Web of Science ®Google Scholar
• Yang JC, Childs R. Immunotherapy for renal cell cancer. J. Clin. Oncol.24, 5576–5583 (2006).
   PubMed Web of Science ®Google Scholar
• Escudier B. Advanced renal cell carcinoma: current and emerging management strategies. Drugs67, 1257–1264 (2007).
   PubMedGoogle Scholar
• Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year followup. J. Urol.148, 1247–1248 (1992).
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Yang JC et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg.210, 474–484 (1989).
   PubMed Web of Science ®Google Scholar
• Gouttefangeas C, Stenzl A, Stevanovic S, Rammensee HG. Immunotherapy of renal cell carcinoma. Cancer Immunol. Immunother.56, 117–128 (2007).
   PubMed Web of Science ®Google Scholar
• Vieweg J, Jackson A. Antigenic targets for renal cell carcinoma immunotherapy. Expert Opin. Biol. Ther.4, 1791–1801 (2004).
   PubMed Web of Science ®Google Scholar
• Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br. J. Cancer57, 239–246 (1988).
   PubMed Web of Science ®Google Scholar
• Southall PJ, Boxer GM, Bagshawe KD, Hole N, Bromley M, Stern PL. Immunohistological distribution of 5T4 antigen in normal and malignant tissues. Br. J. Cancer61, 89–95 (1990).
   PubMed Web of Science ®Google Scholar
• Griffiths RW, Gilham DE, Dangoor A et al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy. Br. J. Cancer93, 670–677 (2005).
   PubMed Web of Science ®Google Scholar
• Carsberg CJ, Myers KA, Evans GS, Allen TD, Stern PL. Metastasis-associated 5T4 oncofoetal antigen is concentrated at microvillus projections of the plasma membrane. J. Cell. Sci.108(Pt 8), 2905–2916 (1995).
   PubMed Web of Science ®Google Scholar
• Carsberg CJ, Myers KA, Stern PL. Metastasis-associated 5T4 antigen disrupts cell-cell contacts and induces cellular motility in epithelial cells. Int. J. Cancer68, 84–92 (1996).
   PubMed Web of Science ®Google Scholar
• Awan A, Lucic MR, Shaw DM et al. 5T4 interacts with TIP-2/GIPC, a PDZ protein, with implications for metastasis. Biochem. Biophys. Res. Commun.290, 1030–1036 (2002).
   Google Scholar
• Ward CM, Barrow K, Woods AM, Stern PL. The 5T4 oncofoetal antigen is an early differentiation marker of mouse ES cells and its absence is a useful means to assess pluripotency. J. Cell. Sci.116, 4533–4542 (2003).
   PubMedGoogle Scholar
• Ward CM, Eastham AM, Stern PL. Cell surface 5T4 antigen is transiently upregulated during early human embryonic stem cell differentiation: effect of 5T4 phenotype on neural lineage formation. Exp. Cell. Res.312, 1713–1726 (2006).
   PubMedGoogle Scholar
• Eastham AM, Spencer H, Soncin F et al. Epithelial–mesenchymal transition events during human embryonic stem cell differentiation. Cancer Res.67, 11254–11262 (2007).
   PubMed Web of Science ®Google Scholar
• Spencer HL, Eastham AM, Merry CL et al. E-cadherin inhibits cell surface localization of the pro-migratory 5T4 oncofetal antigen in mouse embryonic stem cells. Mol. Biol. Cell18, 2838–2851 (2007).
   PubMed Web of Science ®Google Scholar
• Cavallaro U, Christofori G. Cell adhesion and signalling by cadherins and Ig-CAMs in cancer. Nat. Rev. Cancer4, 118–132 (2004).
   PubMed Web of Science ®Google Scholar
• Mulryan K, Ryan MG, Myers KA et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol. Cancer Ther.1, 1129–1137 (2002).
   PubMed Web of Science ®Google Scholar
• Elkord E, Burt DJ, Drijfhout JW, Hawkins RE, Stern PL. CD4+ T-cell recognition of human 5T4 oncofoetal antigen: implications for initial depletion of CD25+ T cells. Cancer Immunol. Immunother.57, 833–847 (2008).
   PubMed Web of Science ®Google Scholar
• Smyth LJ, Elkord E, Taher TE et al. CD8 T-cell recognition of human 5T4 oncofetal antigen. Int. J. Cancer119, 1638–1647 (2006).
   PubMed Web of Science ®Google Scholar
• Harrop R, Connolly N, Redchenko I et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a Phase I/II trial. Clin. Cancer Res.12, 3416–3424 (2006).
   PubMed Web of Science ®Google Scholar
• Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin. Cancer Res.13, 4487–4494 (2007).
   PubMed Web of Science ®Google Scholar
• Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol. Immunother.57, 977–986 (2008).
   PubMed Web of Science ®Google Scholar
• Elkord E, Dangoor A, Drury NL et al. An MVA-based vaccine targeting the oncofetal antigen 5T4 in patients undergoing surgical resection of colorectal cancer liver metastases. J. Immunother.31, 820–829 (2008).
   PubMed Web of Science ®Google Scholar
• Elkord E, Dangoor A, Burt DJ et al. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol. Immunother.58, 1657–1667 (2009).
   PubMed Web of Science ®Google Scholar
• Clarke SL, Betts GJ, Plant A et al. CD4+CD25+FOXP3+ regulatory T cells suppress anti-tumor immune responses in patients with colorectal cancer. PLoS ONE1, E129 (2006).
   PubMed Web of Science ®Google Scholar
• Amato RJ, Shingler W, Goonewardena M et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-α (IFN-α): a Phase 2 trial. J. Immunother.32, 765–772 (2009).
   PubMed Web of Science ®Google Scholar
• Amato RJ, Shingler W, Naylor S et al. Vaccination of renal cell cancer patients with modified vaccinia ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: a Phase II trial. Clin. Cancer Res.14, 7504–7510 (2008).
   PubMed Web of Science ®Google Scholar
• Hawkins RE, Macdermott C, Shablak A et al. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-α. J. Immunother.32, 424–429 (2009).
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Taback B, Sherman W et al. Phase II trial of modified vaccinia ankara (MVA) virus expressing 5T4 and high dose interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J. Transl. Med.7, 2 (2009).
   PubMed Web of Science ®Google Scholar
• Hawkins R, Harrop R, Naylor S et al. TRIST: a randomised, double blind, placebo controlled Phase III study of MVA-5T4 in metastatic renal cancer patients. Presented at: Joint ECCO 15th–34th ESMO Multidisciplinary Congress. Berlin, Germany, 20–24 September 2009.
   Google Scholar
• Griffiths RW, Elkord E, Gilham DE et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol. Immunother.56, 1743–1753 (2007).
   PubMed Web of Science ®Google Scholar
• Thistlethwaite FC, Elkord E, Griffiths RW et al. Adoptive transfer of T(reg) depleted autologous T cells in advanced renal cell carcinoma. Cancer Immunol. Immunother.57, 623–634 (2008).
   PubMed Web of Science ®Google Scholar
• Cheng JD, Babb JS, Langer C et al. Individualized patient dosing in Phase I clinical trials: the role of escalation with overdose control in PNU-214936. J. Clin. Oncol.22, 602–609 (2004).
   PubMed Web of Science ®Google Scholar
• Shaw DM, Connolly NB, Patel PM et al. A Phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br. J. Cancer96, 567–574 (2007).
   PubMed Web of Science ®Google Scholar
• Erlandsson E, Andersson K, Cavallin A et al. Identification of the antigenic epitopes in staphylococcal enterotoxins A and E and design of a superantigen for human cancer therapy. J. Mol. Biol.333, 893–905 (2003).
   PubMed Web of Science ®Google Scholar
• Borghaei H, Alpaugh K, Hedlund G et al. Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer. J. Clin. Oncol.27, 4116–4123 (2009).
   PubMed Web of Science ®Google Scholar
• Shablak A, Hawkins RE, Rothwell DG, Elkord E. T cell-based immunotherapy of metastatic renal cell carcinoma: modest success and future perspective. Clin. Cancer Res.15(21), 6503–6510 (2009).
   Google Scholar
• Mansoor W, Gilham DE, Thistlethwaite FC, Hawkins RE. Engineering T cells for cancer therapy. Br. J. Cancer93, 1085–1091 (2005).
   Google Scholar
• Jiang HR, Gilham DE, Mulryan K, Kirillova N, Hawkins RE, Stern PL. Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors. J. Immunol.177, 4288–4298 (2006).
   PubMed Web of Science ®Google Scholar